Australia | Canada | China | Japan | The Netherlands | United States

E M E R G O 🥑 E U R O P E

24 March 2009

Mr. Jeff Wang LumiQuick Diagnostics, Inc. 2946 Scott Blvd. Santa Clara, CA 95054

Dear Mr.Jeff Wang:

I am writing to inform you that today, we have notified by registered mail the Competent Authority in the following countries:

Austria	Bulgaria	Cyprus	Czech Republic	Denmark	Estonia
Finland	France	Germany	Greece	Hungary	Iceland
Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg
Malta	The Netherla	ands	Norway	Poland	Portugal
Romania	Slovakia	Slovenia	Spain	Sweden	Switzerland
United Kingdo	om				

With this notification, LumiQuick Diagnostics, Inc. has met the requirements of the In-vitro Diagnostics Directive, 98/79/EC for the following devices:

- Adeno/Rota Virus
- Cardiac Marker
- Dengue IgG/IgM Combo (registered only in Italy and The Netherlands)
- Drugs of Abuse
- Fecal Occult Blood (registered only in Italy and The Netherlands)
- H. Pylori Ab/Ag
- HCG
- Legionella (registered only in Italy and The Netherlands)
- LH (registered only in Italy and The Netherlands)
- Strep A (registered only in Italy and The Netherlands)

As of today and without any further notice from the respective Competent Authorities, LumiQuick Diagnostics, Inc. can consider the respective devices and Authorized Representative as officially registered.

If you have any questions, please do not hesitate to contact me.

Yours sincerely,

Rene van de Zande President & CEO Emergo Europe



EmergoEurope.com



Declaration of Conformity

Product name	Model/number	
Infectious diseases HIV I&II Test Strip HIV I&II Test Card HCV Antibody Test Card HBsAg Test Card		71001 71002 71030 71004
MANUFACTURER		
Name of company	Address	Representative
LumiQuick Diagnostics, Inc.	2946 Scott Blvd. Santa Clara, CA 95054 USA	Jeff C. Wang
AUTHORIZED REPRESENTATIVE		
Name of company	Address	Telephone/email
Emergo Europe	Molenstraat 15 2513 BH The Hague, Netherlands	+31.70.345.8570 - phone +31.70.346.7299 - fax service@emergogroup.com
CONFORMITY ASSESSMENT		
Device classification	Route to compliance	Standards applied
Class: Self-Certify		ISO 13485:2003

LumiQuick Diagnostics, Inc. declares that the above mentioned products meet the provision of the Council Directive 98/79/EC for In Vitro Diagnostic Medical Devices and Directive 98/79/EC as transposed in the national laws of the Member States.

COMPANY REPRESENTATIVE: Jeff C. Wang

TITLE: Quality Systems Manager

SIGNATURE:

2017.02.23 1:59:53 -08'00'

DATE: 23/02/2017





Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

LumiQuick Diagnostics, Inc. 2946 Scott Blvd Santa Clara California 95054 USA

Holds Certificate No:

FM 574919

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

The design, development, manufacture and distribution of in vitro diagnostics test kits and reagents used in the diagnosis and management of disease status, including Infectious Diseases tests, Drugs of Abuse tests, Cardiac Monitor tests, Cancer Marker tests, Fertility Hormone tests, ELISA tests & Urine Chemistry tests.

jan CS

For and on behalf of BSI:

Gary E Slack, Senior Vice President - Medical Devices

Original Registration Date: 2011-10-20 Latest Revision Date: 2020-08-31





Effective Date: 2020-10-20 Expiry Date: 2023-10-19

Page: 1 of 1

...making excellence a habit."

This certificate remains the property of BSI and shall be returned immediately upon request. An electronic certificate can be authenticated <u>online</u>. Printed copies can be validated at www.bsigroup.com/ClientDirectory To be read in conjunction with the scope above or the attached appendix.

Americas Headquarters: BSI Group America Inc., 12950 Worldgate Drive, Suite 800, Herndon, VA 20170-6007 USA A Member of the BSI Group of Companies.